Intelligent Bio Solutions completes usability study for FDA 510(k) submission for drug screening system

INTELLIGENT BIO SOLUTIONS INC.

Study confirms system can be effectively administered by operators with no specialist background.
Study conducted with CenExel Clinical Research; 15 operators participated.
On track to submit 510(k) package in H2 2026 for U.S. market clearance for opiate codeine detection.
Part of broader submission program including cut-off, method comparison, interference, and precision studies.
Targets entry into the multi-billion-dollar U.S. drug screening market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.